NCT00947362View on ClinicalTrials.gov

Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

August 1, 2004

Primary Completion Date

December 15, 2007

Study Completion Date

December 15, 2007

Conditions
Wound Healing
Interventions
OTHER

Electro-thermo-coagulation

DRUG

DAC N-055

moist wound treatment plus 0.05 % pharmaceutical chlorite

DRUG

saline

physiological saline

Trial Locations (1)

Unknown

German Medical Service, Kabul

All Listed Sponsors
collaborator

German Medical Service (GMS) in Kabul

OTHER

collaborator

University of Freiburg

OTHER

lead

Waisenmedizin e. V. Promoting Access to Essential Medicine

OTHER

NCT00947362 - Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul | Biotech Hunter | Biotech Hunter